Asthma News

Vitamin D supplements did not reduce asthma exacerbations or improve asthma control among adults or children, according to an updated Cochrane review, contradicting an earlier review showing benefits of supplementation.

During the COVID-19 pandemic, loneliness, family conflict and difficultly accessing health care raised the risk for first-time and recurrent depression among older adults with asthma, according to a study published in Respiratory Medicine.

The FDA has approved tezepelumab-ekko for self-administration in a prefilled, single-use pen among patients aged 12 years and older with severe asthma, according to a press release from the manufacturer.

Children and adolescents with asthma experienced statistically significant higher hospital readmission rates during grass pollen season compared with the rest of the year, according to a study published in Pediatric Allergy and Immunology.

Children with asthma/wheeze demonstrated a strong relationship between age and airway microbiota, with a modest difference observed based on asthma severity, according to study results published in Annals of the American Thoracic Society.

Children with asthma exposed to bushfire smoke demonstrated a clinically important 5% mean decrease in forced vital capacity percent predicted, according to a study published in Pediatric Allergy and Immunology.

People born between January and June in Finland experienced a higher risk for adult-onset asthma than people born later in the year, with a stronger risk among people with atopic asthma, according to a letter published in Asthma.

The U.S. Environmental Protection Agency has proposed changing National Ambient Air Quality standards for fine particulate matter to improve respiratory health, but this update could be stronger, according to the American Lung Association.

Adults with asthma experienced more nonrespiratory diseases and multimorbidity than adults without asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Mepolizumab use was associated with fewer exacerbations, reduced oral corticosteroid use and lower costs among patients with asthma on Medicaid, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.